GSK Seeks Judicial Block on Pfizer and BioNTech’s COVID-19 Vaccine Patent Misconduct Claims

GlaxoSmithKline (GSK) is pushing a Delaware federal judge to block claims from Pfizer and BioNTech, asserting that it has not misused patents related to COVID-19 vaccination technology. GSK argues that neither it nor a predecessor company engaged in any misconduct when filing for those patents. The lawsuit stems from Pfizer and BioNTech’s allegations that GSK’s patent practices were inappropriate, a claim GSK is fervently disputing. For detailed information, visit the original Law360 article.